ICI + TKI Toxicity Management Articles
Last Reviewed March 2025
Disclaimer: This content is provided for educational purposes only and is not a substitute for independent clinical judgment. Always consult official product monographs and prescribing information before making treatment decisions. Do not delay or disregard professional medical advice because of information on this site. Use of this resource does not establish a physician–patient relationship. See the full disclaimer for details.
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Journal of the National Cancer Institute. 2012; 104: 93-113
A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
Therapeutics and clinical risk management. 2022; 18: 683-698
Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
Targeted Oncology. 2020; 15: 549-565
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes
American Journal of Clinical Oncology. 2014; 37(4): 397-403
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies
Expert Opinion in Drug Safety. 2014; 13(4): 497-510
Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor
Clinical genitourinary cancer. 2023; 21(5): e343-351
Optimizing the use of lenvatinib combination with pembrolizumab in patients with advanced endometrial carcinoma
Frontiers in Oncology. 2022; 12: 979519. doi: 10.3389/fonc.2022.979519
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial
Journal of Clinical Oncology. 2022; 40(17): 1929-1938
Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice
Current Oncology. 2022; 29: 6776-6786
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial
European Urology Oncology. 2022; 5(2): 225-234
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
The Oncologist. 2023; 28(6): 501-509
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
British Journal of Cancer. 2020; 123: 898-904
Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach
JCO Oncology Practice. 2020; 16 (Supp 1): 15s - 19s
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review
Cancer Treatment Reviews. 2020; 103: 102333
Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
Oncologist. 2024; 29: 25-35
